That's the interpretation from Tim Anderson, a securities analyst at Sanford Bernstein, who notes that the drugmaker hasn't crowed about receiving a 6-month priority review, even though last Friday was the date by which the agency would have conveyed its decision. In an investor note today, Anderson writes that Lilly filed its request on Dec. 26 and, as a result, the blood thinner will likely receive the standard 10-month review instead.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments